Stock DICOT DICOT PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Dicot Pharma AB

Equities

DICOT

SE0011178458

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 03:30:00 20/06/2024 am IST 		5-day change 1st Jan Change
0.407 SEK +7.11% Intraday chart for Dicot Pharma AB +14.97% +27.99%
06/06 Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs CI
06/05 Dicot Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Dicot Pharma AB Develops LIB-01 into A New Potency Drug with Improved Properties Compared to Currently Available Drugs
CI
Dicot Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Dicot AB Announces Positive Safety and Improved Efficacy Results from Phase 1 Study
CI
Dicot AB Announces Recruitment Completed in Dicot's Phase 1 Trial
CI
Dicot AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Dicot AB Presents Positive Results from the First Part of its Phase 1 Clinical Study
CI
Dicot Files New Manufacturing Technology Patent in Sweden; Stock Rises
MT
Dicot Applies for Patent Covering New Manufacturing Technology
CI
Dicot AB Announces Partial Results from Phase 1 Trial to Be Presented Early Next Year
CI
Dicot AB Initiates Repeat Dosing in its Clinical Study
CI
Dicot AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Dicot AB Initiates Repeated Dosing in Phase I Study
CI
The Second Part of Dicot's Phase 1 Study Starts on October 20, 2023
CI
Swedish Pharma Company Dicot Files Application under Patent Cooperation Treaty
MT
Dicot AB Applies for International Patent Protection
CI
Dicot AB Announces First Participants Dosed in Phase 1 Trial
CI
Dicot AB Applies for US Patent
CI
Dicot AB Announces Clinical Phase 1 Study Starts
CI
Dicot AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Dicot AB Receives Approval to Start Phase 1 Clinical Trial
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DICOT Stock
  4. News Dicot Pharma AB
  5. Highlights